04:00 AM EDT, 08/23/2024 (MT Newswires) -- Moderna ( MRNA ) said early Friday that Japan's Ministry of Health, Labour and Welfare approved its application for an updated formulation of its COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1.

In May, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 family of Omicron subvariants for the 2024/25 national immunization program, the company said.

Price: 81.61, Change: +0.57, Percent Change: +0.70